Subtitle: Market Intelligence, Clinical Progress, and High-Purity Reagents for Metabolic and Neuroendocrine Disorder Development.
TarMart Solution Ecosystem & Related Targets
"Comprehensive reagent toolkit for GALP drug discovery. Select your modality below:"
| Component / Network | Product Description | Product Link |
|---|---|---|
| Antigen | GALP Recombinant Protein High purity (>95%), Endotoxin Controlled. Sequence Verified. Suitable for receptor binding assays. |
View GALP Products |
| Gene Delivery | GALP Promise-ORF / Lentivirus Full-length ORF for stable cell line expression and secretion studies. |
View GALP Products |
| Benchmark Ab | Anti-GALP Biosimilar Antibody Recombinant positive control for ELISA and Western Blot validation. |
View GALP Products |
| Validator | GALP siRNA Set For target knockdown verification in functional assays. |
View GALP Products |
| Related Target A | GALR2 Primary functional GPCR mediating GALP-induced metabolic and anorexigenic pathways. |
View GALR2 Products |
| Related Target B | GALR1 Homolog receptor; essential counter-screening target for selectivity profiling. |
View GALR1 Products |
| Critical Assay Challenge | The TarMart Advantage (Technical Spec) |
|---|---|
| Receptor Selectivity (GALR2 vs. GALR1/3) | Lentivirus Premade Particles for stable cell lines preserving native GPCR conformation. |
| Peptide Stability & Half-life Evaluation | Custom mutant GALP recombinant proteins with verified sequences and high purity (>95%). |
| Lack of Controls | Recombinant benchmark antibodies and sequence-verified positive controls included |
| False Positives in Screening | Validated siRNA sets included for target-specific knockdown verification |
Live GALP R&D Tracker
Market data changes daily. Access the latest global pipeline status directly:
Global Clinical Landscape & Future Outlook
The therapeutic targeting of GALP (Galanin-like peptide) is gaining traction within metabolic disease and neuroendocrine research. As a key hypothalamic peptide regulating food intake, energy expenditure, and LH secretion, GALP represents a promising pathway for obesity and associated metabolic dysfunctions. The global pipeline is transitioning from basic neuropeptide characterization to the engineering of long-acting GALP analogs and selective GALR2 agonists to minimize off-target effects mediated by GALR1.
Competitive Modality & Indication Snapshot
| Modality | Representative Players | Key Indications | Critical Assay Need (Why TarMart?) |
|---|---|---|---|
| Long-acting Peptides | Biotech / Academic Spin-offs | Obesity, Type 2 Diabetes | GALR2/GALR1 selectivity assays (Requires stable GPCR-expressing cell lines via Lentivirus) |
| Small Molecule Agonists | Pharmaceutical Corporates | Metabolic Syndrome, Eating Disorders | High-throughput calcium flux screening (Requires native GPCR conformation) |
| Fc-Fusion Proteins | Translational Research Groups | Hypothalamic Dysfunction | In vitro binding kinetics (Requires high-purity recombinant GALP proteins) |